COVID-19 TESTING 

CONSENT 

SEROLOGY TESTING

As stated in section IV.D. of the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-201, the FDA does not intend to object to the development and distribution by commercial manufacturers, or development and use by laboratories, or serology tests to identify antibodies to SARS-CoV-2, where the test has been validated notification is provided to FDA, and information along the lines of the following is included in the test reports: 

•   This test has not been reviewed by the FDA

•    Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.

•    Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

•    Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

RT-PCR NASAL TESTING

As stated by the CDC in the CDC-006-00019, Revision: 03 manual: The CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the 2019-nCoV in upper and lower respiratory specimens (such as nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates, bronchoalveolar lavage, and nasopharyngeal wash/aspirate or nasal aspirate) collected from individuals who meet 2019-nCoV clinical and/or epidemiological criteria (for example, clinical signs and symptoms associated with 2019-nCoV infection, contact with a probable or confirmed 2019-nCoV case, history of travel to geographic locations where 2019-nCoV cases were detected, or other epidemiologic links for which 2019-nCoV testing may be indicated as part of a public health investigation).

Testing in the United States is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests. Results are for the identification of 2019-nCoV RNA. The 2019-nCoV RNA is generally detectable in upper and lower respiratory specimens during infection. Positive results are indicative of active infection with 2019-nCoV but do not rule out bacterial infection or co-infection with other viruses.

The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities. Negative results do not preclude 2019-nCoV infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must 

be combined with clinical observations, patient history, and epidemiological information: 

CONTACT US

44045 Margarita Rd, Suite 102

Temecula, CA 92591

1(951) 302-1144

D©2020 by CELLUM BioMedical Inc